995 F.3d 123
4th Cir.2021Background
- Actelion sold the branded pulmonary arterial hypertension drug Tracleer (bosentan); Patent No. 5,292,740 expired Nov. 20, 2015.
- From 2009–2014 Actelion allegedly refused to sell samples and contractually blocked distributors from selling samples needed by generic manufacturers to develop bioequivalent generics.
- Actelion filed suit in Sept. 2012; generic manufacturers counterclaimed; Actelion settled with generics in Feb. 2014 (terms undisclosed).
- No generic Tracleer entered the U.S. market for about three years after patent expiration, and plaintiffs allege they paid supracompetitive prices until generics arrived.
- Plaintiffs filed the antitrust class action on Nov. 19, 2018; the district court dismissed most claims as time-barred (statute of limitations) and dismissed certain state-law counts for lack of standing.
- The Fourth Circuit vacated and remanded: (1) plaintiffs’ federal antitrust claims accrued when plaintiffs were first injured (Nov. 2015), (2) continuing-violation rule permits accrual from each supracompetitive sale, and (3) named plaintiffs lack statutory standing to seek relief under states where they made no purchases but class claims may survive Rule 23 review.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Accrual / statute of limitations start date | Accrual began when plaintiffs were first harmed—when patent expired and they paid supracompetitive prices (Nov. 2015). | Accrual began at Actelion’s last overt anticompetitive act (Feb. 2014 settlements); suit filed >4 years later so time-barred. | Accrual occurred when plaintiffs suffered antitrust injury (Nov. 2015); suit timely. |
| Ripeness / speculative future damages | Future damages were not speculative once overcharges occurred; claim for future damages would accrue only when actually suffered. | Plaintiffs suffered injury to future economic interests in 2014, so limitations began then. | Future damages too speculative in 2014; limitations could not run before actual injury. |
| Continuing-violation doctrine (overcharge accrual) | Each supracompetitive sale after patent expiry is a new overt act that restarts limitations. | Post-expiration sales were merely effects of earlier conduct (2014 settlements) and not new unlawful acts. | Each overpriced sale after patent expiry alleged a new injury and restarted the limitations period. |
| Standing to assert out-of-state statutory claims | Class allegations permit inclusion of state-law claims for class members who purchased in other states. | Named plaintiffs lack statutory standing to bring claims under state laws where they made no purchases; counts should be dismissed. | Named plaintiffs lack statutory standing for states where they made no purchases; however, those state-law claims may be considered in Rule 23 class-certification analysis and, if certified, pursued on behalf of class members who did purchase in those states. |
Key Cases Cited
- Zenith Radio Corp. v. Hazeltine Research, Inc., 401 U.S. 321 (recognizes antitrust accrual rule and that speculative future damages do not start limitations clock)
- Charlotte Telecasters, Inc. v. Jefferson-Pilot Corp., 546 F.2d 570 (4th Cir. 1976) (limitations in refusal-to-deal context and continuing-violation discussion)
- United States v. Grinnell Corp., 384 U.S. 563 (defines monopolization elements under §2)
- Klehr v. A.O. Smith Corp., 521 U.S. 179 (continuing violation and accrual principles)
- FTC v. Actavis, Inc., 570 U.S. 136 (Supreme Court treatment of reverse-payment/pay-for-delay schemes)
- Berkey Photo, Inc. v. Eastman Kodak Co., 603 F.2d 263 (2d Cir. 1979) (each overpriced sale gives rise to a new claim for purchasers)
- Detrick v. Panalpina, Inc., 108 F.3d 529 (4th Cir. 1997) (statute of limitations begins to run from date of injury)